Adverse event reports following yellow fever vaccination
Nicole P. Lindsey(Vector (United States)), Edward B. Hayes(Centers for Disease Control and Prevention), Katherine Horan(Centers for Disease Control and Prevention), Betsy Schroeder(Centers for Disease Control and Prevention), Elizabeth D. Barnett(Boston Medical Center), J. Erin Staples(Centers for Disease Control and Prevention), Phyllis E. Kozarsky(Emory University), Barbara A. Slade(Office of the Director), Gary W. Brunette(Centers for Disease Control and Prevention), M. Miles Braun(Center for Biologics Evaluation and Research), Alison F. Hinckley(National Center for Emerging and Zoonotic Infectious Diseases), Elaine R. Miller(National Center for Emerging and Zoonotic Infectious Diseases), Nina Marano(Centers for Disease Control and Prevention)
Cited by 278
Related Papers
Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent
|New England Journal of Medicine|2001|3.7k
Tumor necrosis factor antagonist therapy and lymphoma development: Twenty‐six cases reported to the Food and Drug Administration
|Arthritis & Rheumatism|2002|661
Management of Neonates Born at ≥35 0/7 Weeks’ Gestation With Suspected or Proven Early-Onset Bacterial Sepsis
|PEDIATRICS|2018|462
Case Reports of Heart Failure after Therapy with a Tumor Necrosis Factor Antagonist
|Annals of Internal Medicine|2003|459
Life‐threatening histoplasmosis complicating immunotherapy with tumor necrosis factor α antagonists infliximab and etanercept
|Arthritis & Rheumatism|2002|448